They also reported that primary corticotroph tumor cells harboring BRAF V600E were sensitive to the BRAF inhibitor vemurafenib, indicating its potential efficacy in the treatment of corticotroph tumors with the BRAF V600E mutation [192]. Here, BRAF is linked to neoplasm.